BMI trajectory projector on GLP-1

Why BMI still matters on GLP-1 therapy

BMI is the gatekeeper of GLP-1 access in the United States. Every major payer — commercial, Medicare Part D when applicable, and most state Medicaid programs that cover anti-obesity medications (AOMs) — pulls the same lever when deciding whether to approve Wegovy (semaglutide 2.4mg), Zepbound (tirzepatide), Saxenda (liraglutide 3.0mg), or a compounded equivalent: BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity such as type 2 diabetes, obstructive sleep apnea, dyslipidemia, or hypertension. That is not a marketing number. It is written directly into the FDA labels for Wegovy and Zepbound and mirrored in nearly every prior-authorization template.

What BMI does not tell you is the trajectory. The FDA label says “chronic weight management.” The trials tell you how fast the weight comes off and where it lands. That is what this tool projects. We anchor the curve to three trial-validated endpoints so the chart is not a fantasy:

• Semaglutide 2.4mg once weekly (Wegovy): STEP 1 reported a mean total body weight loss (TBWL) of 14.9% at week 68 in adults without diabetes, versus 2.4% on placebo. Translated: a 225 lb starting weight drifts to about 191 lb at week 68.
• Tirzepatide 15mg once weekly (Zepbound): SURMOUNT-1 showed 22.5% mean TBWL at week 72 on the top dose, and 15.0% on 5mg. That same 225 lb patient lands near 174 lb at 72 weeks on the 15mg dose.
• Liraglutide 3.0mg daily (Saxenda): SCALE Obesity and Prediabetes showed 8% mean TBWL at 56 weeks — the daily dosing and lower ceiling make it the least competitive of the three for pure weight outcomes, though it is still the only FDA-approved pediatric GLP-1 alongside Wegovy.

The shape of the curve matters as much as the endpoint

A flat endpoint hides the messy middle. Real GLP-1 trajectories are not linear. The first 17 weeks on semaglutide and the first 20 weeks on tirzepatide are titration territory — you are not on a therapeutic dose yet. The STEP 1 escalation ramp was 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg, moving up every four weeks. SURMOUNT-1 escalated 2.5 → 5 → 7.5 → 10 → 12.5 → 15mg on a similar every-four-week cadence. Most patients do not begin meaningful appetite suppression until the 1.0mg (semaglutide) or 5mg (tirzepatide) step. That is why the curve in this tool bends gently at first and then steepens between weeks 8 and 24 before gradually flattening toward the trial nadir.

Three concrete implications for your own trajectory:

1. Do not expect 1 lb/week in the first month. It is common to lose 2–5 lb during the 0.25mg or 2.5mg starter — largely water and a slight appetite dampening — and then stall briefly before the next step kicks in.
2. The biggest drop is usually weeks 12–28. This is when therapeutic-dose appetite suppression compounds with a calorie deficit you probably did not have to enforce consciously. Expect 1–2 lb/week during this stretch if everything is going well.
3. The plateau is real and it is expected. By week 40–50 on semaglutide, or week 50–60 on tirzepatide, loss slows dramatically. This is a new set point, not a failure. STEP 4 showed patients who stayed on semaglutide continued losing a small amount through week 68; patients who switched to placebo regained ~7% over the next year.

How to read your BMI zones

The reference lines in the chart at BMI 25 and BMI 30 are more than color-coding. They are payer-coverage thresholds, surgical-candidacy thresholds, and the cutoffs most obesity-medicine physicians use when discussing long-term maintenance. Crossing BMI 30 downward during your treatment year often changes the conversation with your insurer at renewal — some plans require you to stay above a threshold to continue coverage, while others reward the progress. Read your certificate of coverage carefully.

The World Health Organization categories that most US payers mirror:

• BMI 18.5–24.9: normal. GLP-1 indication generally does not apply at this weight unless for diabetes management.
• BMI 25–26.9: overweight. Typically not eligible for Wegovy/Zepbound unless a comorbidity is present.
• BMI 27–29.9: overweight, comorbidity-eligible for anti-obesity indication.
• BMI 30–34.9: class I obesity. Primary AOM indication; fits almost every commercial PA template.
• BMI 35–39.9: class II obesity. Strong AOM indication and bariatric-surgery discussion threshold with a comorbidity.
• BMI ≥ 40: class III (“severe”) obesity. Bariatric surgery is always on the table alongside pharmacotherapy.

Where this tool simplifies — and where it does not

BMI has well-known limitations. A 5′10″ lifter at 215 lb and 16% body fat will register as “obese” at BMI 30.9 while being metabolically healthier than most BMI-22 adults. Muscle mass is the confound. On GLP-1 therapy, lean-mass loss typically accounts for 25–40% of total weight lost without resistance training and high protein intake — which means BMI tracks reasonably well with adiposity in deconditioned starters, and less well in athletes. Use DEXA or a quality bioimpedance reading once a quarter if you care about body composition more than the scale number.

Three things this projector deliberately does not do: (1) adjust for your personal titration speed if you had to slow down due to nausea, (2) account for dose caps that some patients settle on (e.g., maintaining at 1.7mg semaglutide instead of 2.4mg for tolerability), and (3) predict regain after stopping. Use the weight-loss timeline projector for dose-specific curves, the dosage-schedule generator for your personal titration calendar, and the stopping-GLP-1 regain projector for the post-treatment curve.

The “1% per month” heuristic

The calculator also shows a “healthy months to goal” estimate at 1% body weight per month. This is the sustained-pace heuristic taught in most obesity-medicine fellowships. Lose faster than that for long, and two things get worse: (1) sarcopenia accelerates — you start trading muscle for scale weight, and (2) the metabolic adaptations that drive regain (lower resting metabolic rate, elevated ghrelin, suppressed leptin and PYY) deepen. The GLP-1 era has softened the second concern — semaglutide and tirzepatide blunt the hunger hormones that drive regain — but it has not eliminated the first. You still need to protect muscle. See the exercise-on-GLP-1 guide and protein target tool.

Realistic starting expectations by drug and dose

A quick reference for what “on track” looks like at various checkpoints, assuming good tolerance and standard titration:

• Week 12 (month 3): 5–7% TBWL on semaglutide, 6–9% on tirzepatide 7.5–10mg.
• Week 24 (month 6): 9–12% on semaglutide, 13–17% on tirzepatide 10–15mg.
• Week 52 (one year): 13–16% on semaglutide 2.4mg, 18–22% on tirzepatide 15mg.
• Week 72 (nadir): 14–15% on semaglutide 2.4mg, 22–23% on tirzepatide 15mg.

If you are more than 3 percentage points below these at 6 months on-dose, a conversation with your prescriber about dose optimization, adherence, or whether you are a non-responder is warranted. Approximately 13% of patients in STEP 1 and 9% in SURMOUNT-1 did not achieve 5% TBWL — the standard clinical-meaningful-response threshold.

FAQ

My BMI is 26 with prediabetes. Can I get Wegovy or Zepbound?

Under current FDA labeling, Wegovy and Zepbound require BMI ≥ 27 with a weight-related comorbidity, or BMI ≥ 30. At BMI 26, the labeled indication does not apply. Prediabetes alone would meet “comorbidity” for the class, but not the BMI floor. You may still qualify for Ozempic or Mounjaro off-label for weight, depending on your payer, or for compounded semaglutide/tirzepatide through telehealth. See the insurance coverage tool to run your specific plan type.

What BMI will I be at 6 months on tirzepatide?

The SURMOUNT-1 week-24 mean was roughly 15% TBWL on 15mg. If you start at BMI 36 and 220 lb at 5′6″, expect roughly BMI 30.6 at six months — right at the class-I threshold. The projector plots this curve in real time.

Does my goal BMI need to be under 25?

Not necessarily. Obesity-medicine guidelines increasingly set individualized goals based on achievable, sustainable loss — often 10–15% TBWL regardless of BMI category — because the cardiometabolic benefits (ASCVD risk reduction, sleep-apnea improvement, A1C reduction) accrue long before you hit “normal” BMI. SELECT, the cardiovascular outcomes trial for semaglutide 2.4mg, showed a 20% relative risk reduction in MACE at an average TBWL of ~9.4%. Weight is a proxy for health, not the endpoint.

Why does my trajectory flatten before I hit my goal?

Because GLP-1 monotherapy has a dose-dependent ceiling. Semaglutide 2.4mg plateaus around 14–15% TBWL; tirzepatide 15mg plateaus around 22–23%. If your goal requires more than the drug’s ceiling, you will either need combination therapy (semaglutide + metformin + bupropion-naltrexone, bariatric surgery, or a trial of tirzepatide after semaglutide) or a recalibrated goal. Discuss with your obesity-medicine specialist.

My BMI dropped below 27. Will my insurer cancel coverage?

Some do. Read your plan’s “continuation criteria” in the PA template — typical language requires (a) evidence of ongoing benefit (≥5% TBWL maintained) and (b) continued BMI ≥ 27 with comorbidity or ≥ 30. A few plans now cover maintenance regardless of BMI once you have demonstrated response, in line with the AACE/OMA position that obesity is a chronic disease. Use the prior-authorization guide to preview renewal criteria.

Should I use BMI or body-fat percentage?

Track both if you can afford a DEXA scan quarterly ($100–$250 cash). For everyday use, BMI is fine — your insurer does not ask for your body-fat percentage, and the trials reported BMI, so that is how you compare your progress to published data. Muscle loss is the real concern; use a waist circumference tape, grip strength, and your strength-training numbers as the parallel signal.

Related tools

• Weight-loss timeline projector — dose-specific weight curves
• Dosage schedule generator — your personal escalation calendar
• Goal weight timeline — weeks-to-goal estimator
• Stopping GLP-1 regain projector — what happens after discontinuation